Europe's Biggest Pharma Companies Just Sent an SOS

The trial migration numbers tell the story clearly. Europe's share of global clinical trials fell from 22% in 2013 to just 12% in 2023. Over that same period, China's share surged from 5% to 18%. Europe didn't just lose ground; it watched China leapfrog it entirely. The continent lost an estimated 60,000 trial places over the past decade, even as the global trial count rose by 38%.

Follow the Money (It's Not Going to Europe)

Venture capital tells a similar story. U.S. biopharma startups have attracted vastly more health-biotech venture funding than their European counterparts, a gap that has persisted for years.

To put it in perspective: U.S. companies scooped up 63% of global health biotech venture capital over the past decade. And while European biotech VC did hit a record in 2024 (around $6 billion, up from $4.6 billion the year before), the U.S. far outpaced Europe in mega-rounds that year.

The 2025 picture hasn't improved much. European biotech VC is tracking toward another record year, but U.S. funding is still running at roughly triple Europe's pace. The structural imbalance remains firmly in place.

What the CEOs Actually Want

The letter isn't just a complaint; it's a policy wish list. And it's surprisingly specific.

The nine chairs are asking European governments to speed up clinical trial approvals, strengthen intellectual property protections, and give member states more fiscal flexibility to spend on innovative medicines without bumping into EU budget rules. They also want policymakers to treat medicines as strategic infrastructure (think semiconductors or energy) rather than just a line item in the health budget.

On the digital front, they're calling for "sensible" policies that support healthcare modernization. On IP, they want protections closer to what the U.S. offers, since America is consistently ranked first globally for pharmaceutical IP protection. Europe's current incentives, the letter implies, aren't enough to keep companies investing locally when other regions roll out the red carpet.

Brussels Is Listening (Sort Of)

To be fair, the European Commission hasn't been asleep. In December 2025, it proposed the first European Biotech Act, focused on health biotechnology and biomanufacturing. The package aims to simplify regulations, cut time-to-market, speed up trial approvals, and improve funding access for startups and smaller companies.

A second Biotech Act covering industrial applications beyond healthcare is expected later in 2026. The Commission is also pushing a broader pharmaceutical legislation reform to make the EU medicines framework more flexible for innovative biotech therapies.

These are real steps. But the CEO letter suggests they aren't enough, or aren't moving fast enough. Earlier this year, Roche CEO Thomas Schinecker made similar noises, warning that Europe risked falling further behind because of "extraordinary" bureaucracy and "irrational" regulation. The September letter escalates that from one executive's frustration to a collective alarm from nine of Europe's largest drugmakers.

The Real Stakes

Market analysts aren't treating this as an immediate crisis for pharma stock prices. The consensus is that this is a long-game problem: it's about where companies build their next manufacturing plant, where they launch their next drug first, and where the next generation of biotech founders choose to start their companies.

But "long-game" problems have a way of becoming urgent ones. China's approval-date gap versus the U.S. has narrowed by 351 days since 2021, and its gap versus the EU has closed by a staggering 663 days. The catch-up isn't theoretical; it's happening in real time.

Europe still has world-class scientists, strong universities, and deep institutional knowledge in drug development. Nobody disputes that. The question is whether those advantages matter if the regulatory, financial, and political environment keeps pushing companies to invest elsewhere.

Nine pharma chairs just bet their reputations on a public plea for change. Whether European policymakers match that urgency will determine if the continent's biotech sector writes a comeback story, or a eulogy.